Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Asciminib & Chronic myeloid leukemia / Chronic myelogenous leukemia (CML) (Ph+ CML)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

On October 29, 2024, the Food and Drug Administration granted accelerated approval to asciminib for adult patients with newly diagnosed Chronic myeloid leukemia / Chronic myelogenous leukemia (CML) & Mutated variants (“drivers”) (Philadelphia chromosome +) in chronic phase (CP).
AACR FDA Approval Alert 10/29/24

…

References (Sources)

Asciminib as a new option in the treatment of chronic myeloid leukemia
İbiş et al. 2021 Future Oncology 17: 5003-5005
Asciminib in CML after ABL Kinase Inhibitor Failure
Hughes et al. 2019 N Engl J Med 381: 2315-2326
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
Breccia et al. 2021 Expert Opin. Investig. Drugs 30: 803-811
Review

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Asciminib & Chronic myeloid leukemia / Chronic myelogenous leukemia (CML) (Ph+ CML)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat